Short QT syndrome medical therapy

Revision as of 19:04, 3 September 2012 by C Michael Gibson (talk | contribs) (Created page with "__NOTOC__ {{Short QT syndrome}} {{CMG}} ==Overview== ==Short QT Syndrome 1 (SQT1)== The efficacy of pharmacotherapy in preventing ventricular fibrillation has only been ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Short QT syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Type 1
Type 2
Type 3
Type 4
Type 5

Pathophysiology

Causes

Triggers

Differentiating Short QT syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EP studies

Genetic Testing

Treatment

AICD Placement

Medical Therapy

Case Studies

Case #1

Short QT syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Short QT syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Short QT syndrome medical therapy

CDC on Short QT syndrome medical therapy

Short QT syndrome medical therapy in the news

Blogs on Short QT syndrome medical therapy

Directions to Hospitals Treating Short QT syndrome

Risk calculators and risk factors for Short QT syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Short QT Syndrome 1 (SQT1)

The efficacy of pharmacotherapy in preventing ventricular fibrillation has only been studies in patients with SQT1. Given the limited number of patients studied, and the limited duration of follow-up, pharmacotherapy as primary or secondary preventive therapy for patients with SQT1 cannot be recommended at this time. AICD implantation remains the mainstay of therapy in these patients. Pharmacotherapy may play an adjunctive role in reducing the risk of events in patients with an AICD as described below in the indications section.

Patients with Short QT Syndrome 1 (SQT1) have a mutation in KCNH2 (HERG). Class IC and III antiarrhythmic drugs do not produce any significant QT interval prolongation [1][2] . Flecainide has not been shown to consistently reduce the inducibility of ventricular fibrillation.[3] Although it does not prolong the QT interval in SQT1 patients, propafenone reduces the risk of recurrent atrial fibrillation in SQT1 patients.[4]

Quinidine in contrast may be effective in patients with SQT1 in so far as it blocks both potassium channels (IKr, IKs, Ito, IKATP and IK1) and the inward sodium and calcium channels. In four out of four patients, Quinidine prolonged the QT interval from 263 +/- 12 msec to 362 +/-25 msec, most likely due to its effects on prolonging the action potential and by virtue of its action on the IK channels. Although Quinidine was successful in preventing the inducibility of ventricular fibrillation in 4 out of 4 patients, it is unclear if the prolongation of the QT interval by quinidine would reduce the risk of sudden cardiac death.

Although pharmacotherapy can be used to suppress the occurrence of atrial fibrillation in patients with SQT1, AICD implantation is the mainstay of therapy, and pharmacotherapy to prevent sudden death should is only indicated if AICD implantation is not possible.

Among patients with SQT1, Qunidine also:

Indications for Pharmacologic Therapy

The following are indications for pharmacologic therapy of SQTS[5]:

  • In children as an alternate to AICD implantation
  • In patients with a contraindications AICD implantation
  • In patients who decline AICD implantation
  • In patients with appropriate AICD discharges to reduce the frequency of discharges
  • In patients with atrial fibrillation to reduce the frequency of symptomatic episodes

References

  1. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calo L, Brugada R, Antzelevitch C, Borggrefe M, Wolpert C. (2004). "Short QT syndrome: pharmacological treatment". J Am Coll Cardiol. 43 (8): 1494–1499. doi:10.1016/j.jacc.2004.02.034. PMID 15093889.
  2. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M (2005). "Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG". Journal of Cardiovascular Electrophysiology. 16 (1): 54–8. doi:10.1046/j.1540-8167.2005.04470.x. PMC 1474841. PMID 15673388. Retrieved 2012-09-03. Unknown parameter |month= ignored (help)
  3. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calò L, Brugada R, Antzelevitch C, Borggrefe M, Wolpert C (2004). "Short QT syndrome: pharmacological treatment". Journal of the American College of Cardiology. 43 (8): 1494–9. doi:10.1016/j.jacc.2004.02.034. PMID 15093889. Retrieved 2012-09-03. Unknown parameter |month= ignored (help)
  4. Bjerregaard P, Gussak I. Atrial fibrillation in the setting of familial short QT interval. Heart Rhythm 2004; 1: S165 (abstract).
  5. Moreno-Reviriego S, Merino JL.Short QT Syndrome. An article from the E-Journal of the ESC Council for Cardiology Practice. Vol9 N°2, 17 Sep 2010 [1]